Board Change • Jun 05
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Zhiliang Xing was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 08
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: CN¥0.88 (up from CN¥0.58 in FY 2024). Revenue: CN¥1.38b (up 20% from FY 2024). Net income: CN¥368.6m (up 50% from FY 2024). Profit margin: 27% (up from 21% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) exceeded analyst estimates by 5.8%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 29% per year whereas the company’s share price has increased by 30% per year. Announcement • Apr 08
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd., Annual General Meeting, Apr 28, 2026 Shandong Bailong Chuangyuan Bio-Tech Co., Ltd., Annual General Meeting, Apr 28, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Dezhou, Shandong China Price Target Changed • Apr 07
Price target increased by 15% to CN¥31.36 Up from CN¥27.22, the current price target is provided by 1 analyst. New target price is 30% above last closing price of CN¥24.16. Stock is up 91% over the past year. The company is forecast to post earnings per share of CN¥1.12 for next year compared to CN¥0.87 last year. Announcement • Mar 30
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026 Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026 Reported Earnings • Jan 24
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: CN¥0.87 (up from CN¥0.58 in FY 2024). Revenue: CN¥1.38b (up 20% from FY 2024). Net income: CN¥365.8m (up 49% from FY 2024). Profit margin: 27% (up from 21% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) exceeded analyst estimates by 4.6%. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 7.8% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 29% per year whereas the company’s share price has increased by 33% per year. Valuation Update With 7 Day Price Move • Jan 23
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥24.73, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 21x in the Food industry in China. Total returns to shareholders of 144% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥24.79 per share. Announcement • Dec 26
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026 Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026 Buy Or Sell Opportunity • Nov 21
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 6.7% to CN¥19.50. The fair value is estimated to be CN¥24.79, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 62% in 2 years. Earnings are forecast to grow by 59% in the next 2 years. Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: CN¥0.23 (vs CN¥0.15 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.23 (up from CN¥0.15 in 3Q 2024). Revenue: CN¥319.7m (up 11% from 3Q 2024). Net income: CN¥94.8m (up 51% from 3Q 2024). Profit margin: 30% (up from 22% in 3Q 2024). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year whereas the company’s share price has increased by 26% per year. Buy Or Sell Opportunity • Oct 17
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 15% to CN¥19.06. The fair value is estimated to be CN¥24.73, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to grow by 58% in 2 years. Earnings are forecast to grow by 66% in the next 2 years. Announcement • Sep 30
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Buy Or Sell Opportunity • Sep 22
Now 20% undervalued Over the last 90 days, the stock has risen 1.4% to CN¥19.90. The fair value is estimated to be CN¥24.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to grow by 58% in 2 years. Earnings are forecast to grow by 66% in the next 2 years. Buy Or Sell Opportunity • Aug 01
Now 21% undervalued Over the last 90 days, the stock has risen 22% to CN¥19.66. The fair value is estimated to be CN¥24.80, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to grow by 58% in 2 years. Earnings are forecast to grow by 66% in the next 2 years. Reported Earnings • Jul 15
Second quarter 2025 earnings released: EPS: CN¥0.22 (vs CN¥0.15 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.22 (up from CN¥0.15 in 2Q 2024). Revenue: CN¥336.5m (up 21% from 2Q 2024). Net income: CN¥89.2m (up 35% from 2Q 2024). Profit margin: 27% (up from 24% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year whereas the company’s share price has increased by 28% per year. Major Estimate Revision • Jul 03
Consensus EPS estimates increase by 10% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from CN¥0.81 to CN¥0.893. Revenue forecast unchanged at CN¥1.49b. Net income forecast to grow 32% next year vs 22% growth forecast for Food industry in China. Consensus price target of CN¥23.08 unchanged from last update. Share price rose 13% to CN¥22.70 over the past week. Valuation Update With 7 Day Price Move • Jul 02
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥23.03, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 20x in the Food industry in China. Total returns to shareholders of 90% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥24.80 per share. Announcement • Jun 30
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. to Report First Half, 2025 Results on Aug 28, 2025 Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 New Risk • Jun 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risk Dividend is not well covered by cash flows (171% cash payout ratio). Buy Or Sell Opportunity • Jun 10
Now 32% undervalued Over the last 90 days, the stock has risen 11% to CN¥20.38. The fair value is estimated to be CN¥30.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has grown by 25%. Revenue is forecast to grow by 56% in 2 years. Earnings are forecast to grow by 63% in the next 2 years. Valuation Update With 7 Day Price Move • May 21
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥28.08, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 21x in the Food industry in China. Total returns to shareholders of 101% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥30.06 per share. Price Target Changed • May 07
Price target increased by 22% to CN¥30.00 Up from CN¥24.50, the current price target is provided by 1 analyst. New target price is 27% above last closing price of CN¥23.61. Stock is up 8.4% over the past year. The company is forecast to post earnings per share of CN¥1.05 for next year compared to CN¥0.76 last year. Reported Earnings • Apr 30
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.76 (up from CN¥0.60 in FY 2023). Revenue: CN¥1.15b (up 33% from FY 2023). Net income: CN¥245.6m (up 27% from FY 2023). Profit margin: 21% (in line with FY 2023). Revenue missed analyst estimates by 3.8%. Earnings per share (EPS) also missed analyst estimates by 8.3%. Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 8.9% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year whereas the company’s share price has increased by 22% per year. Announcement • Apr 30
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd., Annual General Meeting, May 20, 2025 Shandong Bailong Chuangyuan Bio-Tech Co., Ltd., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Dezhou, Shandong China Valuation Update With 7 Day Price Move • Apr 28
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥20.31, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 19x in the Food industry in China. Total returns to shareholders of 78% over the past three years. Price Target Changed • Apr 16
Price target increased by 7.7% to CN¥24.50 Up from CN¥22.75, the current price target is an average from 3 analysts. New target price is 38% above last closing price of CN¥17.72. Stock is down 8.3% over the past year. The company is forecast to post earnings per share of CN¥1.03 for next year compared to CN¥0.77 last year. New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.9% average weekly change). Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥17.20, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 19x in the Food industry in China. Total returns to shareholders of 38% over the past three years. Announcement • Mar 28
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. to Report Q1, 2025 Results on Apr 30, 2025 Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. announced that they will report Q1, 2025 results on Apr 30, 2025 Reported Earnings • Feb 19
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.77 (up from CN¥0.60 in FY 2023). Revenue: CN¥1.15b (up 33% from FY 2023). Net income: CN¥249.4m (up 29% from FY 2023). Profit margin: 22% (in line with FY 2023). Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) also missed analyst estimates by 7.9%. Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 9.6% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year whereas the company’s share price has increased by 22% per year. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥19.16, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 17x in the Food industry in China. Total returns to shareholders of 84% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥31.29 per share. Announcement • Dec 27
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. to Report Fiscal Year 2024 Results on Apr 30, 2025 Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. announced that they will report fiscal year 2024 results on Apr 30, 2025 Reported Earnings • Oct 31
Third quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.15 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.20 (up from CN¥0.15 in 3Q 2023). Revenue: CN¥289.0m (up 20% from 3Q 2023). Net income: CN¥63.0m (up 26% from 3Q 2023). Profit margin: 22% (up from 21% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to CN¥19.97, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 17x in the Food industry in China. Total returns to shareholders of 68% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥33.11 per share. Announcement • Sep 30
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Reported Earnings • Aug 30
Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.15 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.20 (up from CN¥0.15 in 2Q 2023). Revenue: CN¥279.2m (up 28% from 2Q 2023). Net income: CN¥66.0m (up 42% from 2Q 2023). Profit margin: 24% (up from 21% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 10
Second quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.18 (up from CN¥0.15 in 2Q 2023). Revenue: CN¥279.6m (up 28% from 2Q 2023). Net income: CN¥60.6m (up 30% from 2Q 2023). Profit margin: 22% (in line with 2Q 2023). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year and the company’s share price has also increased by 20% per year. Announcement • Jun 28
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 Valuation Update With 7 Day Price Move • Jun 05
Investor sentiment deteriorates as stock falls 24% After last week's 24% share price decline to CN¥22.95, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 18x in the Food industry in China. Total returns to shareholders of 23% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥34.18 per share. Buy Or Sell Opportunity • Jun 05
Now 33% undervalued after recent price drop Over the last 90 days, the stock has fallen 10% to CN¥22.95. The fair value is estimated to be CN¥34.18, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 81% in 2 years. Earnings are forecast to grow by 96% in the next 2 years. Major Estimate Revision • May 05
Consensus revenue estimates fall by 13% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥1.39b to CN¥1.20b. EPS estimate fell from CN¥1.37 to CN¥1.12 per share. Net income forecast to grow 49% next year vs 25% growth forecast for Food industry in China. Consensus price target of CN¥33.00 unchanged from last update. Share price rose 6.2% to CN¥27.93 over the past week. Announcement • Apr 29
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd., Annual General Meeting, May 17, 2024 Shandong Bailong Chuangyuan Bio-Tech Co., Ltd., Annual General Meeting, May 17, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Dezhou, Shandong China Reported Earnings • Apr 28
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.78 (up from CN¥0.61 in FY 2022). Revenue: CN¥868.3m (up 20% from FY 2022). Net income: CN¥193.0m (up 28% from FY 2022). Profit margin: 22% (up from 21% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) also missed analyst estimates by 1.7%. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Food industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Mar 29
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024 Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024 Reported Earnings • Feb 28
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.78 (up from CN¥0.61 in FY 2022). Revenue: CN¥868.3m (up 20% from FY 2022). Net income: CN¥193.0m (up 28% from FY 2022). Profit margin: 22% (up from 21% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) also missed analyst estimates by 1.7%. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Food industry in China. Announcement • Dec 29
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024 Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024 Price Target Changed • Oct 25
Price target increased by 16% to CN¥26.70 Up from CN¥23.06, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of CN¥26.53. Stock is up 48% over the past year. The company is forecast to post earnings per share of CN¥0.82 for next year compared to CN¥0.61 last year. Reported Earnings • Oct 21
Third quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.15 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.20 (up from CN¥0.15 in 3Q 2022). Revenue: CN¥241.0m (up 53% from 3Q 2022). Net income: CN¥50.2m (up 27% from 3Q 2022). Profit margin: 21% (down from 25% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Food industry in China. Reported Earnings • Aug 04
Second quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.15 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.19 (up from CN¥0.15 in 2Q 2022). Revenue: CN¥218.3m (up 12% from 2Q 2022). Net income: CN¥46.7m (up 24% from 2Q 2022). Profit margin: 21% (up from 19% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Food industry in China. Reported Earnings • Mar 18
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2022 results: EPS: CN¥0.90 (up from CN¥0.64 in FY 2021). Revenue: CN¥721.9m (up 11% from FY 2021). Net income: CN¥150.0m (up 44% from FY 2021). Profit margin: 21% (up from 16% in FY 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) exceeded analyst estimates by 1.1%. Revenue is forecast to grow 36% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Food industry in China. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Oct 30
Third quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.13 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.22 (up from CN¥0.13 in 3Q 2021). Revenue: CN¥157.8m (down 4.8% from 3Q 2021). Net income: CN¥39.5m (up 70% from 3Q 2021). Profit margin: 25% (up from 14% in 3Q 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Food industry in China. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥0.50 (vs CN¥0.21 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.50 (up from CN¥0.21 in 2Q 2021). Revenue: CN¥194.7m (up 13% from 2Q 2021). Net income: CN¥37.7m (up 9.9% from 2Q 2021). Profit margin: 19% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 31%, compared to a 23% growth forecast for the Food industry in China. Reported Earnings • Jul 23
Second quarter 2022 earnings released: EPS: CN¥0.50 (vs CN¥0.21 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.50 (up from CN¥0.21 in 2Q 2021). Revenue: CN¥194.7m (up 13% from 2Q 2021). Net income: CN¥37.6m (up 9.6% from 2Q 2021). Profit margin: 19% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 31%, compared to a 23% growth forecast for the industry in China. Valuation Update With 7 Day Price Move • Jul 22
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥28.26, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 25x in the Food industry in China. Total returns to shareholders of 49% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥25.16 per share. Valuation Update With 7 Day Price Move • May 09
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥36.18, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 23x in the Food industry in China. Total returns to shareholders of 29% over the past year. Reported Earnings • May 02
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: CN¥0.32 (up from CN¥0.18 in 1Q 2021). Revenue: CN¥197.8m (up 48% from 1Q 2021). Net income: CN¥40.7m (up 133% from 1Q 2021). Profit margin: 21% (up from 13% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 8.8%. Earnings per share (EPS) also surpassed analyst estimates by 3.4%. Over the next year, revenue is forecast to grow 30%, compared to a 20% growth forecast for the industry in China. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Mar 04
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CN¥0.95 (down from CN¥1.01 in FY 2020). Revenue: CN¥653.4m (up 31% from FY 2020). Net income: CN¥105.1m (up 10.0% from FY 2020). Profit margin: 16% (down from 19% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 8.8%. Earnings per share (EPS) also surpassed analyst estimates by 9.2%. Over the next year, revenue is forecast to grow 12%, compared to a 17% growth forecast for the industry in China. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥27.58, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 28x in the Food industry in China. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.23 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥165.7m (up 30% from 3Q 2020). Net income: CN¥23.3m (up 9.2% from 3Q 2020). Profit margin: 14% (down from 17% in 3Q 2020). The decrease in margin was driven by higher expenses. Reported Earnings • Aug 25
Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.36 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥172.7m (up 18% from 2Q 2020). Net income: CN¥34.3m (down 4.1% from 2Q 2020). Profit margin: 20% (down from 24% in 2Q 2020). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Aug 12
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥31.39, the stock trades at a trailing P/E ratio of 36.2x. Average trailing P/E is 35x in the Food industry in China. Reported Earnings • Jul 20
Second quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.36 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥172.7m (up 18% from 2Q 2020). Net income: CN¥33.4m (down 6.7% from 2Q 2020). Profit margin: 19% (down from 24% in 2Q 2020). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Jun 05
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥35.99, the stock trades at a trailing P/E ratio of 35.6x. Average trailing P/E is 40x in the Food industry in China. Valuation Update With 7 Day Price Move • May 12
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥31.60, the stock trades at a trailing P/E ratio of 31.3x. Average trailing P/E is 40x in the Food industry in China.